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ARTICLE OPEN
T-bet controls intestinal mucosa immune responses via
repression of type 2 innate lymphoid cell function
N. Garrido-Mesa1,7, J-H. Schroeder1, E. Stolarczyk2,8, A. L. Gallagher3, J. W. Lo1, C. Bailey2, L. Campbell3, V. Sexl4, T. T. MacDonald5,
J. K. Howard2, R. K. Grencis3, N. Powell6 and G. M. Lord1
Innate lymphoid cells (ILCs) play an important role in regulating immune responses at mucosal surfaces. The transcription factor T-
bet is crucial for the function of ILC1s and NCR+ ILC3s and constitutive deletion of T-bet prevents the development of these subsets.
Lack of T-bet in the absence of an adaptive immune system causes microbiota-dependent colitis to occur due to aberrant ILC3
responses. Thus, T-bet expression in the innate immune system has been considered to dampen pathogenic immune responses.
Here, we show that T-bet plays an unexpected role in negatively regulating innate type 2 responses, in the context of an otherwise
intact immune system. Selective loss of T-bet in ILCs leads to the expansion and increased activity of ILC2s, which has a functionally
important impact on mucosal immunity, including enhanced protection from Trichinella spiralis infection and inﬂammatory colitis.
Mechanistically, we show that T-bet controls the intestinal ILC pool through regulation of IL-7 receptor signalling. These data
demonstrate that T-bet expression in ILCs acts as the key transcriptional checkpoint in regulating pathogenic vs. protective mucosal
immune responses, which has signiﬁcant implications for the understanding of the pathogenesis of inﬂammatory bowel diseases
and intestinal infections.
Mucosal Immunology (2019) 12:51–63; https://doi.org/10.1038/s41385-018-0092-6
INTRODUCTION
Innate lymphoid cells (ILCs) play a crucial role in early mucosal
immune defence, inﬂammation and tissue remodelling.1 Based
on the transcription factors that govern their differentiation,
function and signature cytokine production, mature IL-7Rα+ ILCs
can be classiﬁed into three groups: ILC1s, which express T-bet
and produce IFNγ and TNFα; ILC2s that express high levels of
GATA-3 and produce type 2 cytokines; and ILC3s that express
RORγt, produce IL-22 and IL-17,1 and can be further subdivided
based on the expression of the chemokine receptor CCR6 and
the natural cytotoxicity receptor NKp46 or NCR, encoded by the
gene Ncr1.2
In addition to ILC1s, T-bet is co-expressed with NKp46 in NCR+
ILC3s (in which it is co-expressed with RORγt) and cNK cells.2,3
T-bet is essential for ILC development, as germline deletion of T-
bet results in a complete loss of NCR+ ILCs,2,4 and it is also
involved in NCR+ ILC function. The ﬁrst description of this came
from studies in the TRUC mouse (T-bet−/− x RAG2−/− ulcerative
colitis), which develop spontaneous colitis dependent on IL-17-
producing ILC3s.5 Furthermore, within the CCR6− ILC3 subset, T-
bet expression is required for CCR6-/low ILC3s differentiation into
NCR+ ILC3s and subsequent IFNγ production.2,6,7T-bet is also
induced in human and murine ILC2s, resulting in the production
of IFNγ.8–11 Among several cytokines, IL-12 and IL-18 appear to be
the main driver of these effects, however their pathophysiological
relevance is still unknown.
The absence of ILC1s in T-bet−/− mice is linked to increased
susceptibility to enteric infections.2,6,12–14 We have previously
reported the phenotype of TRUC mice that develop spontaneous
colitis, which is dependent on IL-17-producing CCR6+ ILC3s in the
absence of adaptive immunity.5 Increased frequency of inﬂam-
matory ILC1s has also been found in inﬂamed intestine from
Crohn’s disease patients.6,13,15 However, whether T-bet expression
in ILCs drives protective or pathogenic mucosal immune
responses in the presence of an intact immune system still needs
to be elucidated. Importantly, we have recently shown that
alterations in T-bet binding are critical determining factors in
driving mucosal inﬂammatory diseases in humans.16
Here, we deﬁne a previously unrecognised role for T-bet in ILC2
function and its signiﬁcance in the control of helminth infection
and the pathogenesis of dextran sodium sulphate (DSS)-induced
colitis. In the presence of an intact immune system, speciﬁc
targeting of T-bet in ILCs results in the development of protective
intestinal ILC2 responses. Crucially, T-bet regulates responsiveness
of the intestinal ILC pool to IL-7 signalling. Therefore, we propose
that T-bet acts as a key molecular regulator, controlling both
pathogenic and protective immune responses in the intestine in a
context-dependent manner.
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RESULTS
ILC2s are expanded in immunocompetent T-bet-deﬁcient mice
We found markedly increased numbers of ILCs in the spleen,
mesenteric lymph nodes (MLN) and colon lamina propria (cLP) of
T-bet−/−mice compared to wild type (WT) mice (Fig. 1a). As
previously reported, NCR+ ILCs were virtually absent in
T-bet−/−mice and IFNγ production by ILCs was decreased4 (Fig. 1b),
similar to the situation with T-bet-deﬁcient NK and T cells
(Supplemental Fig. 1). To date, there are no data informing how
T-bet might impact ILC2 numbers in the gut. Strikingly, the
KLRG1+ICOS+ ILC2s were markedly expanded in the cLP of T-bet−/
−mice (Fig. 1c). Likewise, the proportion of IL-5 and
Fig. 1 ILC2s are expanded in immunocompetent T-bet-deﬁcient mice. a–g Flow cytometry analysis of the different ILC populations in WT and
T-bet−/− mice showing: a Representative plots showing the ILC population within CD45+ cells in the spleen. Absolute cell numbers of ILCs in
the indicated tissues; b Representative plots and percentage of NKp46+ cells within the ILC population and IFNγ-producing ILCs within the
CD45+ live cell population in the cLP; c Representative plots showing the ILC2 population within cLP ILCs. Absolute cell numbers of ILC2s and
percentage of ILC2s within the CD45+ live cell population in the cLP; d Representative plots showing IL-13 and IL-5 cytokine expression by
KLRG1+ ILCs from the cLP. Percentage of IL-13+ and IL-5+ ILCs within the CD45+ live cell population in the cLP; e Representative plots showing
the ILC2 population within splenic ILCs. Absolute cell numbers of ILC2s and percentage of ILC2s within the CD45+ live cell population in the
indicated tissues. ILCs are deﬁned as CD45+Lin-IL-7Rα+ cells; ILC2s are deﬁned as CD45+Lin-IL-7Rα+ICOS+KLRG1+ (cLP) and as CD45+Lin−IL-
7Rα+CD25+c-Kit+ (spleen and MLN) cells. f-g IL-13 concentration in the supernatants of cultured: f T-cells-depleted leucocytes from the spleen
and cLP and g FACS-sorted ILC2s from the cLP of WT and T-bet−/−mice, unstimulated (-) or stimulated with IL-25 or/and IL-33 (50 ng/ml, 24 h),
or PMA (50 ng/ml) and ionomycin (1 μg/ml). ILC2s were FACS-sorted as CD45+Lin-IL-7Rα+ICOS+KLRG1+ cells. Data are expressed as mean ±
SEM and are representative of at least three independent experiments (n= 3). ns: non-signiﬁcant; *p < 0.05; **p < 0.01; ***p < 0.001. See also
Supplemental Figs. 1–4
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IL-13-producing ILC2s were also signiﬁcantly increased in the cLP
of T-bet−/−mice (Fig. 1d). This ILC2 expansion was also observed in
the spleen and MLN of T-bet−/−mice where the number of
CD25+cKit+ ILC2s was increased by up to 8- and 3-fold,
respectively (Fig. 1e) (Supplemental Fig. 2). This phenotype was
independent of the reduction in IFNγ production that charac-
terises T-bet−/− mice, as no differences were observed in ILC2
numbers between WT and Ifng−/− mice (Supplemental Fig. 3). To
further investigate the functionality of ILC2s in the absence of
T-bet, T-cell-depleted leucocytes from the spleen and the cLP of
T-bet-deﬁcient and sufﬁcient mice were stimulated overnight with
IL-25 or IL-33, two potent stimulators of ILC2s,17,18 which resulted
in higher levels of IL-13 detected in the culture supernatants of T-
bet-deﬁcient cells (Fig. 1f). This observation was in line with
greater abundance of IL-13-expressing cells among T-bet-deﬁcient
ILC2s upon a 4-hour in vitro stimulation with IL-25 or IL-33. IL-25
and IL-33 receptor expression in ILC2s from T-bet−/− mice was
similar to that observed in WT ILC2s (Supplemental Fig. 4). When
T-bet−/−and T-bet+/+ cultures where activated with PMA and
ionomycin overnight no differences in IL-13 levels in the culture
supernatants were observed, suggesting that IL-25/IL-33 speciﬁc
responsive cells were responsible for the differential IL-13
production detected. To further address whether the enhanced
expression of IL-13 in this model was due to increased ILC2s
numbers within the ILC population or due to a higher ILC2 per cell
responsiveness, ILC2s from T-bet−/−and WT mice were FACS-
sorted and equal numbers of cells were stimulated in vitro with IL-
25 and IL-33. IL-13 levels in culture supernatants were signiﬁcantly
higher in ILC2 cultures from T-bet−/−mice than from T-bet-
sufﬁcient animals (Fig. 1g). Therefore, we concluded that T-bet
deﬁciency leads to the expansion of ILC2s and enhances ILC2
cytokine production in response to IL-25 and IL-33.
ILC2 expansion also occurs in the context of T-bet deﬁciency in the
absence of an adaptive immune system
T-bet deﬁciency in the innate immune system has been previously
linked with aberrant IL-17 production by ILCs, as seen in the TRUC
model, a colony of T-bet−/− x RAG2−/− that develops microbiota-
dependent colitis in response to Helicobacter typhlonius.5 We have
now taken advantage of a colitis-free colony of T-bet−/− x RAG2−/−
non-ulcerative colitis mice or TRnUC mice and evaluated ILC2
responses in this context. Higher numbers of ILCs and ILC2s were
also found in the spleen, MLN and cLP of TRnUC mice when
compared with RAG2−/− mice (Fig. 2a–c), and the numbers of IL-5
and IL-13-producing ILCs in the cLP was also substantially
increased (Fig. 2d).
In vitro targeting of T-bet in ILCs promotes the ILC2 phenotype
The direct role of T-bet in ILC function was also evidenced in T-bet
deletion studies in ex vivo puriﬁed ILCs. In vitro treatment of ILCs
from T-betﬂ/f mice19 with TAT-Cre recombinase caused a reduction
in T-bet expression to levels close to those detected in ILCs from T-
bet−/− mice (Fig. 3a), and consequently their ability to produce
IFNγ was also reduced, while they produced more IL-17A (Fig. 3a,
b). Interestingly, this was accompanied by an increase in GATA-3
and KLRG1 expression (Fig. 3c) and a higher production of IL-5 and
IL-13, as detected by ﬂow cytometry and in the culture
supernatants of cells exposed to the Cre-recombinase (Fig. 3d,
e). These ﬁndings are consistent with a transition towards an ILC2
phenotype and demonstrate a novel role for T-bet in ILCs,
controlling the stability of ILC1s while repressing ILC2 activity and
development.
De-repression of IL-7Rα in T-bet−/− ILCs stabilises IL-7 signalling
IL-7 signalling has a critical role in ILC development and function20
and decreased IL-7Rα expression by ILC2s in response to retinoid
acid has been related to reduced proliferation and tissue
accumulation of ILC2s.21 We observed that IL-7Rα expression
was signiﬁcantly higher in ILCs from T-bet−/− than from WT mice
(Fig. 4a). Interestingly, while GATA-3 has previously been
described to positively regulate IL-7Rα expression in ILC3s,22 we
observed the levels of GATA-3 expression in total ILCs from
T-bet−/− and WT mice to be found equivalent (Fig. 4b), even
though higher numbers of GATA-3+ ILCs were found in T-bet−/−
mice (Fig. 4c). IL-7 signalling activates STAT-523 and in T-cells,
inducing GATA-3 and IL-13 expression and driving Th2 differentia-
tion.24,25 Considering that GATA-3 is also critical for ILC2
maintenance and IL-13 production,26–31 ILCs may also require an
IL-7-driven STAT-5 signal to induce GATA-3 and ILC2 differentia-
tion. Interestingly, after IL-7 stimulation, we found increased
phosphorylation of STAT-5 in ILCs from T-bet−/− mice in
comparison with T-bet-sufﬁcient ILCs (Fig. 4d, e), while no
activation of STAT-3 or STAT-4 was induced (Supplemental Fig. 5).
Considering the role of IL-2 in ILC biology, STAT-5 activation was
also analysed in ILCs upon stimulation with IL-2 and no signiﬁcant
differences were observed between T-bet- sufﬁcient and T-bet-
deﬁcient ILCs (Supplemental Fig. 6A). In addition, the expression of
the IL-2 receptor CD25 was comparable in ILC2s from WT and T-
bet−/− mice (Supplemental Fig. 6B). Of note, higher frequencies of
Ki67-expressing ILC2s were observed in ILC cultures from
T-bet−/−spleen, MLN and cLP (Fig. 4f). Thus, in the absence of T-
bet, de-repression of IL-7Rα in ILCs conferred enhanced IL-7
signalling capacity, driving STAT-5 phosphorylation and poten-
tially mediating the expansion and increased cytokine production
activity of ILC2s.
Development of an in vivo model of selective deletion of T-bet in
ILCs
We have shown that deletion of T-bet triggers ILC2s expansion
and activity both in vivo and in vitro. However, T-bet deﬁciency in
other non-ILC immune cells or the lack of NCR+ ILCs in T-bet−/−
mice per se, could potentially impact on this phenotype. In
addition, previous reports have suggested that ILC homoeostasis
is altered in models lacking adaptive immunity32,33 and it has
been shown that ILCs and T cells compete for IL-734 suggesting
that ILCs may expand in models lacking adaptive immunity as a
result of the higher availability of IL-7. Therefore, we sought to
develop a model of selective deletion of T-bet in ILCs in an
otherwise intact immune system, which would allow for a more
accurate in vivo interrogation of the role of T-bet in ILC
homoeostasis and function.
T-bet expression in ILCs has been reported to be linked to the
expression of the natural cytotoxicity receptor NKp46 (encoded by
Ncr1) (Supplemental Fig. 7), expressed in cNK cells, ILC1s and a
subset of ILC3s.3 Therefore, to selectively target T-bet in ILCs, T-
betﬂ/ﬂ mice19 were crossed with the Ncr1-iCreTg transgenic
mouse,35 which expresses the Cre-recombinase under the control
of the Ncr1 promoter, a strategy previously used to delete GATA-3
speciﬁcally in ILCs.36
Genomic PCR in FACS-sorted cells evidenced the presence of
the T-bet-recombined locus in cNK cells and NKp46-expressing or
NCR+ ILCs, but not in NCR−ILCs or CD3+ cells (Fig. 5a). Importantly,
no reduction in T-bet expression was observed in NKp46+ CD3+
cells and the ability of naïve CD4+ T-cells to differentiate into Th1
or Th2 cells was also unaffected (Supplemental Fig. 8). In contrast
to the work of others using a different genetic approach to drive
Cre-recombinase,37 efﬁcient deletion of T-bet in ILCs was achieved
in this model. T-bet expression in ILCs from the Ncr1-iCreTg x
T-betﬂ/ﬂ mouse was equivalent to that of ILCs from T-bet−/− mice
(Fig. 5b, left). Although the T-bet recombined locus was also
observed in NK cells, in these cells T-bet expression was only
reduced by approximately 25% (Fig. 5b, c), and this had no effect
on their maturation or their ability to produce IFNγ (Supplemental
Fig. 9), as occurs in germline T-bet deﬁciency. Notably, and in
contrast to previous reports describing the absence of NCR+ ILCs
in T-bet−/− mice,2,4 we found that selective deletion of T-bet in
T-bet controls intestinal mucosa immune responses via repression of type. . .
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NCR+ ILCs did not affect their development or cytokine-producing
ability. NCR+ ILCs were found in the cLP of Ncr1-iCreTg x T-betﬂ/ﬂ
mice at similar percentages and numbers as in WT littermate
controls (Fig. 5d), and their IFNγ producing ability remained
unaffected (Fig. 5e). These ﬁndings support the Ncr1-iCreTg x T-
betﬂ/ﬂ or T-betΔNCR+ILC mouse as an in vivo model of selective
deletion of T-bet in ILCs in an immunocompetent background.
Importantly, the number of ILCs in the spleen and MLN of T-
betΔNCR+ILC mice was increased (Fig. 5f) and they expressed higher
cell surface IL-7Rα (Fig. 5g), as previously observed in T-bet−/−
mice. Similarly, ILC2s were found to be substantially increased in
the spleen and MLN of T-betΔNCR+ILC mice (Fig. 5h) and stimulation
of cLP leucocytes resulted in higher IL-13 and IL-5 production by
ILC2s (Fig. 5i). These results show that in vivo targeting of T-bet in
ILCs selectively mediates the expansion of ILC2s, reproducing the
ﬁndings observed in vitro and establishing a central role for T-bet
in the development and function of ILC2s.
T-bet deﬁciency enhances the mucosal immune response against
intestinal parasites
We next studied the functional implications of loss of T-bet in ILCs
in the development of mucosal immune responses. ILC2
Fig. 2 ILC2 expansion also occurs in T-bet−/− x RAG2−/−mice. Flow cytometry analysis of the different ILC populations in RAG2−/−and TRnUC
mice showing: a Representative plots showing the ILC population within CD45+ cells from the spleen. Absolute numbers of ILCs in the
indicated tissues; b Representative plots showing the ILC2 population within ILCs from the spleen and absolute numbers of ILC2s in the
spleen and MLN; c Representative plots showing the ILC2 population within ILCs from the cLP and absolute numbers of ILC2s in the cLP;
d Representative plots showing IL-5 and IL-13 expression by KLRG1+ ILCs and numbers of IL-5 and IL-13-producing ILCs in the cLP. Data are
expressed as mean ± SEM and are representative of at least three independent experiments (n= 3). *p < 0.05; **p < 0.01; ***p < 0.001. ILCs are
deﬁned as CD45+IL-7Rα+ cells and ILC2s as CD45+IL-7Rα+cKit+CD25+ (spleen and MLN) and CD45+IL-7Rα+KLRG1+ICOS+ (cLP) cells
T-bet controls intestinal mucosa immune responses via repression of type. . .
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responses are essential in mediating immunity against intestinal
parasites,17,18,38,39 and previous studies have shown that T-bet-
deﬁcient mice display an accelerated expulsion of Trichinella
spiralis.40 In agreement with this, we observed that T. spiralis worm
expulsion was enhanced in T-bet−/− mice compared to WT mice
8 days after the infection, while after 14 days both groups had
equally eliminated the worms (Fig. 6a). Haematoxylin and eosin
(H&E) histological analysis revealed that at day 8 the small
intestine (SI) muscle layer in T-bet−/− mice was thicker than in WT
mice, the villus length was preserved and the depth of the crypts
was reduced (Fig. 6b, c). Regarding the ILC population, signiﬁ-
cantly higher numbers of ILCs and especially ILC2s were found in
the spleen and MLN of infected T-bet−/− mice (Fig. 6d, e) and
higher numbers of IL-5 and IL-13-producing ILC2s were evidenced
in the spleen of T-bet−/− mice during the early response to the
parasite (Fig. 6f). A link between T-bet-deﬁcient ILCs and
accelerated worm expulsion was conﬁrmed in the T-betΔNCR+ILC
model. Eight days after the infection with T. spiralis, the number of
worms remaining in the SI of T-betΔNCR+ILC mice was signiﬁcantly
lower than in WT mice (Fig. 6g). In fact, worm expulsion in
T-betΔNCR+ILC mice was as marked as in T-bet−/− mice, supporting
the involvement of T-bet-deﬁcient ILCs in this process.
T-bet deﬁciency in ILCs protects from the development of
inﬂammatory colitis
To address the functional relevance of these ﬁndings in the
context of type 1 mucosal inﬂammation, we induced acute colitis
in T-betΔNCR+ILC mice with DSS.41 It has previously been shown
that ILC2s play a protective role in DSS colitis,42 therefore, we
hypothesised that the expansion of ILC2s observed in mice lacking
T-bet in the ILC compartment would be protective from colitis.
Interestingly, T-betΔNCR+ILC mice developed a milder systemic
disease in response to DSS, as evidenced by their signiﬁcantly
reduced weight loss and lower disease activity index (DAI) score in
comparison with control mice (Fig. 7a). The colon weight/length
ratio in colitic T-betΔNCR+ILC mice was also signiﬁcantly lower
(Fig. 7b). Histopathological examination of the colon revealed a
reduced degree of colonic damage in T-betΔNCR+ILC mice (Fig. 7c,
d). There was no difference in colitis between WT mice or control
mice containing only the Ncr1-iCre transgene, or the ﬂoxed T-bet
allele (T-betﬂ/ﬂ) (Supplemental Fig. 10). Strikingly, marked eosino-
philic inﬁltration was observed in T-betΔNCR+ILC mice (Fig. 7d, e),
whereas the presence of neutrophils in the cLP in WT and T-
betΔNCR+ILC mice was very similar (Fig. 7f). Eosinophil activation
and accumulation in tissues during inﬂammation has been
Fig. 3 In vitro targeting of T-bet in ILCs promotes the ILC2 phenotype. a–d Representative ﬂow cytometry plots and histograms showing:
a T-bet expression and IFNγ production (numbers indicate mean ﬂuorescent intensity (MFI)) and percentage of T-bet+ ILCs; b IL-17A and IFNγ
production (numbers indicate percentage of cells); c GATA-3 and KLRG1 expression and d IL-5 and IL-13 production (numbers indicate
percentage of cells); e Concentration of IL-13 in the culture supernatants. FACS-sorted cLP ILCs (CD45+Lin−IL-7Rα+cells) from T-betﬂ/ﬂ mice
were treated with TAT-Cre recombinase (100 μg/ml) and maintained in culture with IL-2 (100 UI/ml) and IL-7 (10 ng/ml) for a week. Intracellular
cytokine staining was performed after PMA and ionomycin stimulation. For IL-13 determination in the culture supernatant cells were
previously stimulated with IL-25 and IL-33 (50 ng/ml) for 24 h. Data are expressed as mean ± SEM and are representative of at least three
independent experiments (n= 3)
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attributed to resident ILC2s through IL-5 and IL-13 expression.43
Thus, we evaluated IL-13 production in ex vivo colonic organ
cultures, ﬁnding increased levels of this cytokine in T-betΔNCR+ILC
mice (Fig. 7g). In addition, qPCR analysis of cytokine transcripts in
colonic tissue revealed high expression of IL-13, IL-5 and IL-4 in
colitic T-betΔNCR+ILC mice (Fig. 7h) while no differences were
observed in IL-17A or IFNγ expression or production (Fig. 7g, h).
Furthermore, cLP ILCs from T-betΔNCR+ILC DSS-colitis mice
produced higher IL-13 and IL-5 after stimulation than ILCs from
DSS-WT mice (Fig. 7i), whereas IL-17A and IFNγ production by ILCs
were equivalent in both groups (Fig. 7j). Therefore, T-bet deletion
in ILCs may lead to the development of a type 2 mucosal immune
response after an inﬂammatory insult with the potency of
attenuating tissue damage.
DISCUSSION
Here, we report a previously unappreciated role for T-bet in the
homoeostasis and function of ILC2s. We have demonstrated
that T-bet deﬁciency in ILCs favours ILC2 responses, conferring
protection against intestinal parasites and modulating the
immune response during colitis. In this context, T-bet
expression in ILCs in the absence of an adaptive immune
system works to dampen pro-inﬂammatory responses, as TRUC
mice have been found to develop colitis driven by aberrant
numbers of IL-17-producing ILCs.5 By contrast, we now report
that in a more physiologically relevant setting, in the presence
of an otherwise intact immune system, T-bet deﬁciency in ILCs
results in the development of protective mucosal immune
responses.
We have established a new model of selective deletion of T-bet
in ILCs, the T-betΔNCR+ILC mouse. The effects of T-bet in other
immune cell types can interfere with or disguise the phenotypes
attributed to ILCs. We have shown that as opposed to what
observed in animals with a germline deletion of T-bet, NCR+ ILCs
can be found in the T-betΔNCR+ILC model, and the function and
development of these and other NKp46-expressing cells remains
largely unaffected. By developing this model, we have also
provided further insights into the role of T-bet in NCR+ ILC
development. In contrast to what has been previously reported for
T-bet−/−mice,2,4 when T-bet deletion is under the control of Ncr1
expression, NCR+ ILCs can be found in the intestinal mucosa in the
same numbers as in T-bet-sufﬁcient animals, and their ability to
produce IFNγ is unaffected.
Fig. 4 T-bet de-repression of IL-7Rα in ILCs stabilises IL-7 signalling and STAT-5 phosphorylation. a Density of IL-7Rα expression in ILCs from the
cLP of WT vs. T-bet−/−mice measured by ﬂow cytometry. Fold change expressed as mean ± SEM vs. WT group. b GATA-3 expression levels in ILCs
from WT vs T-bet−/− mice. c Absolute cell numbers of GATA-3+ ILCs in the cLP of WT and T-bet−/− mice. d–e Representative ﬂow cytometry
analysis of the phosphorylation of STAT-5 in ILCs from the spleen (d) and cLP (d–e) of WT and T-bet−/−mice after stimulation with: d IL-7 (50 ng/
ml, 60min) and e IL-7 (20 ng/ml, 30 or 60min). Numbers indicate the median ﬂuorescence intensity (MFI). f Representative ﬂow cytometry
analysis of Ki67 expression in ILC2s from the spleen, MLN and cLP of WT and T-bet−/−mice. Data are expressed as mean ± SEM and are
representative of at least three independent experiments (n= 3).*p < 0.05; ****p < 0.0001. ILCs were deﬁned as CD45+Lin-IL-7Rα+ and ILC2s as
CD45+Lin-IL-7Rα+ICOS+cKit+CD25+ (spleen and MLN) and CD45+Lin−IL-7Rα+KLRG1+ICOS+ (cLP) cells. See also Supplemental Figs. 5 and 6
T-bet controls intestinal mucosa immune responses via repression of type. . .
N Garrido-Mesa et al.
56
Mucosal Immunology (2019) 12:51 – 63
In addition, by using the T-betΔNCR+ILC model we have
conﬁrmed a role for T-bet in controlling ILC2 responses, although
these cells express no detectable amounts of T-bet. IFNγ has been
reported to limit type 2 cytokine expression in lung ILC2s,
however,44–46 ILC2 expansion in the absence of T-bet is
independent of IFNγ as the number of ILC2s in IFNγ-deﬁcient
mice was not altered. One of the potential mechanisms of T-bet
mediated control of the intestinal ILC pool, is in the regulation of
IL-7 signalling. Similar to our previous ﬁndings in CD4+ T-cells
where we demonstrated that T-bet binds to the IL-7Rα promoter,5
T-bet acts as a transcriptional repressor of the Il7ra gene in ILCs,
and increased IL-7Rα expression in ILCs from a T-bet-deﬁcient
background leads to increased activation of STAT-5 upon IL-7
stimulation. Importantly, we have found that the enhanced ILC
expression of IL-7Rα in the absence of T-bet occurs in the context
of normal GATA-3 levels, providing further evidence that T-bet is
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acting as a direct transcriptional repressor of IL-7Rα, rather than
indirectly via a change in GATA-3 expression. Increased IL-7
responsiveness in the absence of retinoic acid signalling has been
related to higher ILC2 proliferation and accumulation.21 Interest-
ingly, we have demonstrated that RARα and T-bet interact to
control T-cell plasticity and lineage stability, providing a potential
unifying mechanism for these observations.47 STAT-5 activation
may stabilise GATA-3 expression in ILCs, which would drive ILC2
differentiation and account for the higher numbers of ILC2s
observed in T-bet-deﬁcient animals. Genome-wide analysis has
revealed how T-bet and GATA-3 binding sites are related to each
other.48,49 In Th1 cells T-bet sequesters GATA-3 away from Th2
genes preventing their activation, and loss of T-bet induces
default commitment to Th2 and Th17 lineages.50 Similarly, T-bet
could also interact with GATA-3 in ILCs, and it is therefore possible
that T-bet loss in ILCs induces default commitment to ILC2s. In
fact, transitioning regulatory elements in ILC precursors have been
recently reported to be enriched with motifs for both T-box and
GATA-3 families, suggesting the existence of a prior stage in which
the level of these two transcription factors could determine a
particular ILC fate.51 Therefore, T-bet deﬁciency in ILCs could
potentially allow for the activation of GATA-3 related genes
mediating the expansion of group 2 ILCs.
The transcriptional control of ILCs represents an important
mechanism by which T-bet regulates immune responses that is
likely to be relevant for understanding the pathogenesis of
different inﬂammatory conditions. In the intestinal mucosa, ILCs
are potent innate immune effector cells that promote resistance to
pathogens and maintain homoeostasis.52 Group 2 ILCs respond to
epithelial-derived cytokines such as IL-25 and IL-33 and promote
immunity to intestinal parasites in mice.17,18,38,39 We have shown
that increased ILC2 numbers in T-bet-deﬁcient mice promote early
worm expulsion upon T. spiralis infection. Moreover, challenging
these mice with DSS resulted in the development of a milder
intestinal inﬂammatory process. Instead of IFNγ- and IL-17-
mediated colitis, these mice developed a type 2 intestinal immune
response that prevented the deleterious effects of an aberrant
activation of the immune system. These results suggest that T-bet
expression in ILCs can regulate both pro- and anti-inﬂammatory
processes in the intestinal mucosa. Thus, tuning the levels of T-bet
expression in ILCs could potentially represent a tool to optimise
immune responses, allowing a selective regulation of protective
vs. pathological ILC responses, which could be relevant for the
treatment of IBD and other ILC-mediated conditions.
Our results here shed new light on the role that T-bet plays in
ILC homoeostasis and function in health and disease. T-bet has
been proven essential for ILC1 and ILC3 biology. We have now
demonstrated that T-bet also modulates ILC2 responses in the
intestinal lamina propria. Therefore, we propose T-bet as a critical
mediator of ILC responses, establishing a mechanism for its role as
a key regulator of mucosal immunity.
METHODS
Animals
BALB/c and C57BL/6 WT (Charles River) and T-bet−/− and RAG2−/−
(Jackson labs) mice were sourced commercially. T-betﬂ/ﬂ mice were
previously generated by our group.19 Ncr1-iCreTg mice were a gift
from Veronica Sexl, University of Veterinary Medicine Vienna35 and
tissues from Ifng-/- mice were provided by Professor Anne O’Garra,
The Francis Crick Institute, UK. TRnUC and T-betΔNCR+ILC mouse
strains were bred locally by breeding BALB/c RAG2−/− and
T-bet−/− mice, and Ncr1-iCreTg and T-betﬂ/ﬂ mice respectively. T-
betﬂ/ﬂ, Ncr1-iCreTg littermates and C57BL/6 mice were all used as
controls for experiments involving T-betΔNCR+ILC mice; no differ-
ences were observed between T-betﬂ/ﬂ and Ncr1-iCreTg mice when
compared to C57BL/6 animals in any of the experiments. Male
mice of 6-12 weeks of age were used. All mice were housed in
speciﬁc pathogen–free facilities at King’s College London Biologi-
cal Services Unit, University of Manchester Biological Services
Facility or at Charles River Laboratories.
Isolation of cells
cLP cells were isolated as previously described53 using a digestion
media composed of HBSS without Mg2+ or Ca2+ (Invitrogen), 2%
of fetal calf serum (FCS Gold, PAA Laboratories), and 0.5 mg/ml
collagenase D, 10 μg/ml DNase I and 1.5 mg/ml dispase II (all
Roche). The cLP lymphocyte-enriched population was harvested
from a 40–80% Percoll (GE Healthcare) gradient. Splenic and MLN
cells were isolated by mechanical dissociation through 70-μm
ﬁlters into a single-cell suspension.
Flow cytometry
Flow cytometry was performed as previously described.5 GATA-3
staining was performed using the Transcription factor buffer set
and pSTAT-5, 3 and 4 were measured using BD Phosﬂow kit (BD
Biosciences). In phosphoﬂow experiments cells were stimulated
with IL-7 (50 ng/ml) or IL-2 (50 ng/ml) in cytokine-free ex vivo 20
medium (Lonza) at 37 °C for 30 or 60min. Antibodies were from
eBioscience unless otherwise stated. A lineage cocktail was used
including antibodies against CD3, CD45R, CD11b, TER-119 and Ly-
6G, and additional CD5, CD19 and FcεRI in some experiments. For
a complete list of the antibodies used see supporting documents.
Samples were acquired using an LSRFortessa™ cell analyser
(Becton Dickinson, USA) and data were analysed using FlowJo
software (Tree Star, USA).
Cell sorting
Single-cell suspensions were stained with ﬂuorescently labelled
antibodies as described and analysed and sorted (purity > 98%)
using a BD FACSAria III cell sorter (BD Biosciences). For ILCs, antibodies
against CD45, lineage markers and IL-7Rα were used to separate
CD45+Lin−IL-7Rα+ cells. ILC2s were sorted as ICOS+CD25+cK-
it+CCR6− ILCs (spleen) and KLRG1+ICOS+CCR6− ILCs (cLP).
Fig. 5 Selective deletion of T-bet in ILCs in vivo. a Agarose gel electrophoresis (1.5%) of PCR products following speciﬁc genomic DNA PCR for
the Cre-mediated excised locus of T-bet in FACS-sorted NK cells (CD45+IL-7Rα−NK1.1+NKp46+), T-cells (CD3+), NCR+ ILCs (CD3-IL-
7Rα+NKp46+) and NCR− ILCs (CD3−IL-7Rα+NKp46−) from T-betΔNCR+ILC mice. b Representative histograms showing intracellular staining for
T-bet in ILCs from the cLP and in NK cells from the spleen of WT, T-betΔNCR+ILC and T-bet−/−mice. c Analysis of T-bet expression by western blot
in FACS-sorted NK cells from the spleen. d Representative ﬂow cytometry plots showing the percentage of NCR+ ILCs and percentage within
the CD45+ live cell population and absolute numbers of NCR+ ILCs in the cLP of WT, T-betΔNCR+ILC and T-bet−/−mice. e Representative ﬂow
cytometry plots showing IFNγ production by NCR+ ILCs in the cLP of WT and T-betΔNCR+ILC mice. f Representative ﬂow cytometry plots
showing the percentages of ILCs in the spleen and absolute numbers of ILCs in the indicated tissues. g Density of IL-7Rα expression in ILCs
from WT vs. T-betΔNCR+ILC mice measured by ﬂow cytometry. Fold change expressed as mean ± SEM vs. WT group. h Representative ﬂow
cytometry plots showing the percentages of ILC2s within the CD45+ live cell population in the spleen and absolute cell numbers of ILC2s in
the indicated tissues of WT, T-betΔNCR+ILC and T-bet−/−mice. i Representative ﬂow cytometry analysis of IL-5 and IL-13 expression by ILCs and
absolute cell numbers of IL-5+ and IL-13+ ILCs in the cLP of WT and T-betΔNCR+ILC mice. Data are expressed as mean ± SEM and are
representative of at least three independent experiments (n= 3). ns: non-signiﬁcant; *p < 0.05; **p < 0.01. ILCs were deﬁned as CD45+Lin−IL-
7Rα+ cells and ILC2s were deﬁned as CD45+Lin–IL-7Rα+CD25+ICOS+ (spleen and MLN) and CD45+Lin–IL-7Rα+ICOS+KLRG1+ (cLP) cells. See
also Supplemental Figs. 7–9
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In vitro studies
For ILC2s cytokine production assays in vitro, unfractionated
lymphocytes depleted of CD4+ T-cells using MACS MicroBead
Technology (Miltenyi Biotec) or FACS-sorted ILC2s from the spleen
and cLP of T-bet−/− and WT mice were cultured at a concentration
of 5 × 106 lymphocytes/ml or 400.000 ILC2s/ml in complete RPMI-
1640 medium (PAA Laboratories) supplemented with 10% FCS,
2mM L-glutamine and nonessential amino acids (Sigma-Aldrich),
10 mM HEPES (Fisher Scientiﬁc), and 1mM sodium pyruvate,
50 μM 2-mercaptoethanol, 100 IU/ml penicillin and 100 μg/ml
streptomycin (Invitrogen). IL-25 and/or IL-33 (50 ng/ml), or PMA
(50 ng/ml) and ionomycin (1 μg/ml) were added to the cultures.
Fig. 6 T-bet deﬁciency enhances the mucosal immune response against intestinal parasites. a Number of worms in the SI of WT and T-bet−/−
mice 8 and 14 days after the infection with 300 larvae of T. spiralis. b Representative H&E-stained histological sections and c Quantiﬁcation of
the muscle thickness, villus length and crypt depth in SI histological sections from T. spiralis infected mice. d Representative ﬂow cytometry
analysis of CD45+ cells from the spleen of T. spiralis infected mice showing percentages of ILCs and of ILC2s in T-bet−/− mice 8 days after the
infection. e Absolute cell numbers of ILCs and ILC2s in the indicated tissues, and f Absolute cell numbers of IL-5+ and IL-13+ ILC2s in the
spleen of T. spiralis infected mice, 8 and 14 days after the infection. g Number of worms in the SI of WT, T-bet−/− and T-betΔNCR+ILC mice 8 and
14 days after the infection with 300 larvae of T. spiralis. Data are expressed as mean ± SEM and are representative of at least three independent
experiments (n= 5). ns: non-signiﬁcant; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. ILCs are deﬁned as CD45+Lin−IL-7Rα+ cells and ILC2s
as CD45+Lin−IL-7Rα+CD25+c-Kit+ (spleen and MLN) and CD45+Lin−IL-7Rα+KLRG1+ (cLP) cells
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After 24 h of culture at 37 °C, supernatants were collected and
stored at –80 °C until used for cytokine measurement by ELISA.
For in vitro TAT-Cre recombinase deletion of T-bet, 1 × 106 cells/ml
FACS-sorted ILCs from T-betﬂ/ﬂ mice were cultured in serum-free
complete RPMI-1640 medium. TAT-Cre recombinase (100 μg/ml)
(EMD Millipore) was added to the cultures for 1 h, and then washed
with media supplemented with 20% FCS. The cells were kept in
culture with IL-2 (100UI/ml) and IL-7 (10 ng/ml) for a week.
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Intracellular cytokine, surface markers and transcription factor
expression were analysed by ﬂow cytometry. For IL-13 determination
cells were previously stimulated with IL-25 and IL-33 (50 ng/ml) and
after 24 h of culture at 37 °C, supernatants were collected and stored
at –80 °C until used for cytokine measurement by ELISA. In separate
experiments, cells were isolated after 4 h and analysed by ﬂow
cytometry.
Trichinella spiralis infection
The maintenance, infection and recovery of T. spiralis was carried
out as previously described.54 WT, T-bet−/−and T-betΔNCR+ILC mice
were infected with 300 T. spiralis muscle larvae and were sacriﬁced
8 or 14 days after the infection. At necropsy representative whole
gut specimens (0.5 cm length) were taken from the SI (9 cm from
the pylorus) for histology studies and RNA extraction. Adult worms
were recovered from the SI and counted as previously described.55
Spleen and MLN were harvested for ﬂow cytometry.
DSS-induced colitis
Colitis was induced by adding 3% DSS (36-50 KDa, MP
Biomedicals, Ontario, USA) to the drinking water for 5 days.
Non-colitic mice were administered sterile drinking water. Mice
were sacriﬁced 10 days after the beginning of the experiment. An
average daily DAI score was calculated according to the criteria
proposed previously.56 At necropsy, representative whole gut
specimens (0.5 cm length) were taken from the distal inﬂamed
region of the colon for histology studies and RNA extraction. In all,
3 mm punch biopsies (Miltex) were obtained for colon explant
cultures, performed as described previously.5 The remaining
colonic tissue was used for LP cell isolation and ﬂow cytometry.
Histology
Colon and SI cross-sections were ﬁxed in 10% paraformaldehyde
and embedded in parafﬁn blocks. Full-thickness sections of 5 μm
were stained with haematoxylin and eosin (H&E). SI muscle
thickness, villus length and crypt length in T. spiralis experiments
and colonic microscopic damage in DSS-colitis experiments
(criteria described in Supplemental table) were evaluated by
pathologist observers (AG and TM, respectively) who were blinded
to the experimental groups.
Cytokine determination
Intracellular cytokine expression was measured by ﬂow cytometry
after cells were stimulated with PMA (50 ng/ml) and ionomycin (1
μg/ml) for 4 h. IL-13 concentration in culture supernatants was
measured by ELISA (eBioscience) and IFNγ and IL-17A concentra-
tion was measured using a BD Cytometric Bead Array Mouse Th1/
Th2/Th17 Cytokine kit (BD biosciences).
Real-time PCR
Snap frozen colon segments were homogenised using a Tissue
lyzer II with a Stainless-Steel Bead (5 mm) and RNA was extracted
using a RNeasy® Mini Kit (all Qiagen). cDNA was generated with a
cDNA synthesis kit (Bioline). mRNA transcripts were quantiﬁed by
quantitative PCR using TaqMan gene expression assays for IL-13
(Mm0043204_m1), IL-5 (Mm00439646_m1), IL-4 (Mm00445259_
m1), IFNγ (Mm01168134_m1) and IL-17A (Mn00439619_m1)
(Applied Biosystems, Warrington, UK). Gene expression was
normalised to the expression of β-actin (4352341E) to generate
ΔCT values and relative abundance was quantiﬁed using the 2−ΔCT
method.
Western blotting
T-bet expression analysis by western blot was performed as
described elsewhere.57 Anti-T-bet antibody (eBio4B10,
eBioscience) was used at a dilution of 1/1000. A primary antibody
against β-actin (1/1000) (13E5, Cell Signalling Technology,
Danvers, USA) was used as loading control. Peroxidase-
conjugated anti-mouse IgG (1/5000) (GE Healthcare UK Limited)
was used as secondary antibody. All antibody incubations were
performed at 4 °C overnight.
Statistics
Results are expressed as mean ± SEM. Non−parametric data were
analysed using a Mann−Whitney U-test or two-way analysis of
variance (ANOVA), parametric data was analysed using a two-
tailed t-test, as appropriate, using GraphPad Prism 5.0 (GraphPad
Inc., USA). ns: non−signiﬁcant; *p < 0.05; **p < 0.01; ***p < 0.001;
****p < 0.0001.
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Fig. 7 T-bet deﬁciency in ILCs protects from the development of inﬂammatory colitis. a Weight increment (%) (left panel) and disease activity
index (DAI) values (right panel) of NC and DSS WT and T-betΔNCR+ILC mice over the 10-day experimental period (n= 10). DAI values were
calculated based on the criteria proposed previously.56 b Colon weight/length ratio and c Spleen weight of NC and DSS WT and T-betΔNCR+ILC
mice (n= 10). c Microscopic damage score assigned to colonic sections according the criteria described in supplemental table (n= 10) and
d Representative H&E-stained colonic sections from NC and DSS WT and T-betΔNCR+ILC (arrows indicate eosinophils). e, f Representative ﬂow
cytometry plots showing the presence of e SiglecF+CD11b+ eosinophils and f Gr1+CD11b+ neutrophils, in the cLP of WT and T-betΔNCR+ILC
mice. g Concentration of the indicated cytokines in the culture supernatants of explant colon organ cultures and h Real-time PCR measuring
the transcripts of the indicated cytokines in the colon of NC and DSS WT and T-betΔNCR+ILC mice (n= 3). Fold change expressed as mean ±
SEM vs. NC WT group. i, j Representative ﬂow cytometry analysis of intracellular cytokine production showing: i IL-5 and IL-13 production and
percentages of IL-5+ and IL-13+ ILCs within the CD45+ live cell population (n= 3) and j IL-17 and IFNγ production by cLP ILCs from DSS WT
and T-betΔNCR+ILC mice. Data are expressed as mean ± SEM and are representative of at least three independent experiments. *p < 0.05; **p <
0.01; ***p < 0.001. ILCs are deﬁned as CD45+Lin−IL-7Rα+ cells and ILC2s as CD45+Lin−IL-7Rα+CD25+c-Kit+ (spleen and MLN) and
CD45+Lin−IL-7Rα+KLRG1+ (cLP) cells. Eosinophils and neutrophils are gated on live CD45+ cells. NC and DSS represent non-colitic and DSS-
treated mice, respectively. See also Supplemental Fig. 10
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